


Curriculum Vitae

	Name in Full	Yeonjung Ha
	Country	South Korea
	Affiliation	CHA Bundang Medical Center, CHA University
	Email	yeonjung.ha@gmail.com
Educational Background		
2003-2009	Inje University College of Medicine, M.D. (summa cum laude)	
2012-2014	University of Ulsan College of Medicine, M.S.	
2014-2017	University of Ulsan College of Medicine, Ph.D.	
Professional Career		
2009	Internship, Asan Medical Center	
2010-2013	Residency, Internal Medicine, Asan Medical Center	
2013	Short-term Training, Prince of Wales Hospital, Hong Kong, China	
2014-2015	Clinical Fellowship, Gastroenterology, Asan Medical Center	
2016-2023	Assistant Professor, CHA Bundang Medical Center	
2017-2019	Visiting Scientist, Mayo Clinic, United States	
2024-	Associate Professor, CHA Bundang Medical Center	
Research Field		
Endocrine and cardiovascular aspects of MASLD Clinical outcomes of hepatocellular carcinoma Application of artificial intelligence in hepatology Sarcopenia		



1. Oh S, Lee J, Chun S, et al. Interaction between the PNPLA3 Gene and Nutritional Factors on NAFLD Development: The Korean Genome and Epidemiology Study. *Nutrients* 2022;15(1) (In eng). DOI: 10.3390/nu15010152.
2. Yang H, Kang B, Ha Y, et al. High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma. *JHEP reports : innovation in hepatology* 2023;5(4):100672. (In eng). DOI: 10.1016/j.jhepr.2023.100672.
3. Cho H, Lee YB, Ha Y, et al. Changes in liver stiffness values assessed using transient elastography in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study. *BMC Gastroenterol* 2023;23(1):210. (In eng). DOI: 10.1186/s12876-023-02846-9.
4. Ha Y, Lim J, Chon YE, et al. Five-year on-treatment variables-based PPACS model predicts subsequent hepatocellular carcinoma in entecavir/tenofovir-treated patients. *Int J Cancer* 2023;153(12):2045–2054. (In eng). DOI: 10.1002/ijc.34704.
5. Cheon J, Kim H, Kim HS, et al. Atezolizumab plus bevacizumab in patients with child-Pugh B advanced hepatocellular carcinoma. *Ther Adv Med Oncol* 2023;15:17588359221148541. (In eng). DOI: 10.1177/17588359221148541.
6. Choi KY, Kim TY, Chon YE, et al. Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction-associated fatty liver disease. *Journal of cachexia, sarcopenia and muscle* 2023;14(6):2747–2756. (In eng). DOI: 10.1002/jcsm.13351.
7. Chon YE, Park SJ, Park MY, et al. Extrahepatic Malignancies Are the Leading Cause of Death in Patients with Chronic Hepatitis B without Cirrhosis: A Large Population-Based Cohort Study. *Cancers (Basel)* 2024;16(4) (In eng). DOI: 10.3390/cancers16040711.
8. Chon YE, Kim DY, Kim M, et al. Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after Atezolizumab/Bevacizumab Failure: A real-world study. *Clin Mol Hepatol* 2024 (In eng). DOI: 10.3350/cmh.2023.0553.
9. Zhang H, Targher G, Byrne CD, et al. A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease. *Hepatol Int* 2024 (In eng). DOI: 10.1007/s12072-024-10702-5.
10. Lee S, Lee K, Park J, et al. Global burden of vaccine-associated hepatobiliary and gastrointestinal adverse drug reactions, 1967-2023: A comprehensive analysis of the international pharmacovigilance database. *J Med Virol* 2024;96(7):e29792. (In eng). DOI: 10.1002/jmv.29792.



11. Lee K, Park J, Lee J, et al. Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK. *Clinical and molecular hepatology* 2024;30(4):943–958. (In eng). DOI: 10.3350/cmh.2024.0203.
12. Jeong J, Jo H, Park J, et al. Global Estimates of Vaccine-Associated Hepatic Autoimmune Disorders and Their Related Vaccines, 1968-2024: An International Analysis of the WHO Pharmacovigilance Database. *Int Arch Allergy Immunol* 2024:1–7. (In eng). DOI: 10.1159/000542865.
13. Hahn JW, Woo S, Park J, et al. Global, Regional, and National Trends in Liver Disease-Related Mortality Across 112 Countries From 1990 to 2021, With Projections to 2050: Comprehensive Analysis of the WHO Mortality Database. *J Korean Med Sci* 2024;39(46):e292. (In eng). DOI: 10.3346/jkms.2024.39.e292.
14. Ha Y, Lee S, Lim J, et al. A Machine Learning Model to Predict De Novo Hepatocellular Carcinoma Beyond Year 5 of Antiviral Therapy in Patients With Chronic Hepatitis B. *Liver Int* 2025;45(4):e16139. (In eng). DOI: 10.1111/liv.16139.
15. Choe HJ, Choi YM, Ha Y, et al. The Role of the Parametric Thyroid Feedback Quantile Index in Cardiovascular Risk Evaluation Among Euthyroid Koreans. *J Clin Endocrinol Metab* 2025 (In eng). DOI: 10.1210/clinem/dgaf046.
16. Ha Y. Diagnosis and Management of Benign Liver Tumors. *Korean J Gastroenterol* 2025;85(3):314–318. (In eng). DOI: 10.4166/kjg.2025.046.
17. Ha Y. Not All Child-Pugh B Is the Same: Refining Immunotherapy Eligibility in Hepatocellular Carcinoma. *Liver Int* 2026;46(3):e70566. (In eng). DOI: 10.1111/liv.70566.
18. Song DS, Yoo JJ, Song JE, et al. KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications 2026. *Clin Mol Hepatol* 2026;32(3):961–1028. (In eng). DOI: 10.3350/cmh.2026.0281.
19. Song JE, Ha Y, Chang Y, Yoo JJ. Diagnostic Performance of Serum-Ascites Albumin Gradient: A Systematic Review and Meta-Analysis. *Gut Liver* 2026 (In eng). DOI: 10.5009/gnl260180.

